SembioSys Receives License Payment From Lonza

SemBioSys Genetics, a biotechnology company developing a broad pipeline of protein-based pharmaceutical and non-pharmaceutical products, announced receipt of the second and final scheduled license payment from its royalty-bearing license and sales agreement with Lonza Inc. The agreement provides Lonza with the global rights to SemBioSys' DermaSphere Oleosome Technology for use in personal care markets. Lonza launched its first DermaSphere-based product (Natrulon OSF) under its Natrulonline of natural ingredients in Q4 2004.

()a href="http://www.newswire.ca/en/releases/archive/May2005/26/c3986.html" target="_blank">Canada NewsWire Group